BridgeBio Pharma is set to release its quarterly earnings on February 24, 2026. Here are key points investors should consider before the announcement:
* Analysts expect a loss per share of $0.67.
* Investors are hoping for positive guidance for the next quarter.
Let’s review past performance:
| Quarter | EPS Estimate | Actual EPS | Price Change |
| — | — | — | — |
| Q3 2025 | -0.82 | -0.95 | -5.00% |
| Q2 2025 | -0.68 | -0.95 | -9.00% |
| Q1 2025 | -1.00 | -0.88 | 5.00% |
| Q4 2024 | -1.09 | -1.40 | 0.00% |
BridgeBio Pharma’s share price has been steadily increasing over the past 52 weeks, up 100%. Long-term shareholders are likely optimistic about this earnings release.
Please note that Benzinga does not provide investment advice and is not responsible for any losses incurred by users of its content.
Source: https://www.benzinga.com/insights/earnings/26/02/50781681/insights-ahead-bridgebio-pharmas-quarterly-earnings